Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 33NIH 6NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Leukemia 10Myelodysplastic Syndromes 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 4Leukemia, Biphenotypic, Acute 4Neuroblastoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Ganglioneuroblastoma 3Sarcoma, Ewing 2Preleukemia 2Precancerous Conditions 2Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Bone Marrow Diseases 2Anemia, Refractory, with Excess of Blasts 2Sarcoma 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1

Interventions

Radiotherapy 3Methotrexate 3Cytarabine 3Cyclosporine 3Peripheral Blood Stem Cell Transplantation 2Daunorubicin 2Cyclophosphamide 2Busulfan 2zosuquidar trihydrochloride 1sargramostim 1merphos 1hydrocortisone hemisuccinate 1Whole-Body Irradiation 1Thioguanine 1Stem Cell Transplantation 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methoxsalen 1Idarubicin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Cyclosporins 1Colony-Stimulating Factors 1Asparaginase 1Antilymphocyte Serum 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Anemia, Refractory, with Excess of Blasts × Busulfan × Clear all
NCT00005866 2015-03-06

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

SWOG Cancer Research Network

Phase 3 Completed
240 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00077116 2012-07-16

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
31 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡